# Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer

> **NCT00315211** · PHASE2 · TERMINATED · sponsor: **Aultman Health Foundation** · enrollment: 7 (actual)

## Conditions studied

- Mediastinal Neoplasms

## Interventions

- **DRUG:** Intravenous Topotecan
- **DRUG:** Intravenous Docetaxel

## Key facts

- **NCT ID:** NCT00315211
- **Lead sponsor:** Aultman Health Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2007-06
- **Final completion:** 2007-11-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00315211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00315211, "Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00315211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*